LexDanaLexDanabeta
Inventor

Roger A. Smith

Inventor
Chester Springs, PA, US

Overview

68→
Patents
1991–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 68 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
C07DHeterocyclic compounds28%
A61KPreparations for medical, dental or toiletry purposes18%
C07CAcyclic or carbocyclic compounds5%
G01NInvestigating or analysing materials by determining their chemical or physical properties5%
C07KPeptides4%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
Y02ATechnologies for adaptation to climate change2%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
PatentTitleYear
10,869,872Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways202010,751,332Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer202010,647,720Pyrimido-pyridazinone compounds and methods of use thereof202010,471,051Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer201910,350,167Targeted delivery of drugs to the myometrium via anti-oxytocin receptor antibodies201910,316,080Protein-polymer-drug conjugates201910,294,212Inhibitors of the kynurenine pathway201910,226,468Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways201910,188,654Uses of pyrimido-pyridazinones to treat cancer201910,183,944Pyrimido-pyridazinone compounds and methods of use thereof20199,896,445'Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer'20189,815,811'Inhibitors of the kynurenine pathway'20179,757,382'Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways'20179,533,981'Pyridine derivatives'20179,499,495'Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways'20169,382,277'Pyrimido-pyridazinone compounds and methods of use thereof'20169,371,316'Pyridine derivatives'20169,266,873'Pyridine derivatives'20169,199,975'Biaryl imidazole derivatives for regulating CYP17'20159,180,115'Cyclohexylamines'20159,145,411'Substituted amino-pyrimidine derivatives'20159,115,092'Substituted quinazoline and pyrido-pyrimidine derivatives'20158,865,741'Aminoindane compounds and use thereof in treating pain'20148,841,330'Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors'20148,809,372'Pyridine derivatives'20148,729,079'Pyrimido-pyridazinone compounds and methods of use thereof'20148,685,418'Cyclohexylamines'20148,580,798'Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders'20138,440,662'Substituted quinazoline and pyrido-pyrimidine derivatives'20138,207,166'Substituted pyrazolyl urea derivatives useful in the treatment of cancer'20128,207,172'Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders'20128,124,630'ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors'20128,101,773'Hydroxy methyl phenyl pyrazolyl urea compounds useful in the treatment of cancer'20128,076,488'Bicyclic urea derivatives useful in the treatment of cancer and other disorders'20118,013,166'Preparation and use of aryl alkyl acid derivatives for the treatment of obesity'20117,968,576'Preparation and use of aryl alkyl acid derivatives for the treatment of obesity'20117,928,239'Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas'20117,928,227'2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders'20117,897,623'ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors'20117,838,524'Substituted pyrazolyl urea derivatives useful in the treatment of cancer'20107,759,376'Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity'20107,750,017'Heterocycles'20107,625,915'Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas'20097,528,255'Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors'20097,517,880'Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas'20097,511,048'Pyrimidothienoindazoles'20097,423,156'Preparation and use of aryl alkyl acid derivatives for the treatment of obesity'20087,384,639'Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule'20087,371,763'Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas'20087,351,834'ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors'20087,329,670'Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas'20087,235,576'Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors'20077,091,228'Preparation and use of aryl alkyl acid derivatives for the treatment of obesity'20067,071,207'Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity'20066,960,601'Preparation and use of imidazole derivatives for treatment of obesity'20056,958,219'Method for detecting a gram-negative bacterial autoinducer molecule'20056,919,371'2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists'20056,713,059'Antibodies raised against immunogenic conjugates of gram-negative bacterial autoinducer molecules'20046,699,860'Di-substituted aminomethyl-chroman derivative beta-3 adrenoreceptor agonists'20046,660,752'2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists'20036,395,282'Immunogenic conjugates of Gram-negative bacterial autoinducer molecules'20026,344,476'Inhibition of p38 kinase activity by aryl ureas'20026,187,799'Inhibition of raf kinase activity using aryl ureas'20016,114,118'Method of identification of animals resistant or susceptible to disease such as ruminant brucellosis, tuberculosis, paratuberculosis and salmonellosis'20005,718,903'Vaccine comprising Brucella abortus which has O polysaccharide antigen absent'19985,190,860'Differential diagnostic assay for brucellosis'19935,158,936'Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors'19925,055,451'Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors'1991

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1991–1992Based in Milton, CA· patent location history
1993–2000Based in College Station, TX, US· patent location history
2001–2014Based in Madison, CT, US· patent location history
2002–2008Based in Rochester, NY, US· patent location history
2003–2009Patents assigned to BAYER PHARMACEUTICALS CORP (14)· patent assignee history
2009–2014Patents assigned to BAYER HEALTHCARE LLC (12)· patent assignee history
2011–2014Patents assigned to DUMAS JACQUES (6)· patent assignee history
2011–2020Based in Chester Springs, PA, US· patent location history
2013–2014Patents assigned to ENDO PHARMACEUTICALS INC (4)· patent assignee history
2014–2020Patents assigned to ASANA BIOSCIENCES LLC (20)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ASANA BIOSCIENCES LLC202014–2020
BAYER PHARMACEUTICALS CORP142003–2009
BAYER HEALTHCARE LLC122009–2014
DUMAS JACQUES62011–2014
ENDO PHARMACEUTICALS INC42013–2014
Locations
LocationPatentsSpan
Chester Springs, Pennsylvania, US292011–2020
Madison, CT, US292001–2014
Rochester, New York, US42002–2008
College Station, Texas, US31993–2000
Milton, CA21991–1992